09:55 AM EDT, 03/23/2026 (MT Newswires) -- Knight Therapeutics ( KHTRF ) was at last look up more than 1% Monday after saying it received acceptance from the Toronto Stock Exchange (TSX) to amend its previously announced notice of intention to make a Normal Course Issuer Bid (NCIB) to increase the maximum number of common shares that it intends to buy back for cancellation.

It now intends to repurchase, during the 12-month period ending Aug. 21, 2026, 6.2-million common shares from 3-million common shares, about 10% of the public float of common shares as at Aug. 8, 2025. All other terms and conditions of the NCIB remain unchanged.

During the period from Aug. 22, 2025 to Mar. 19, 2026, inclusively, the company bought back 1.8-million common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted average price per share of $6.08.

Knight Therapeutics ( KHTRF ) also amended its automatic share purchase plan with its broker to reflect the increased number of common shares authorized for repurchase under the amended NCIB.

Shares of the company were last seen up 1.25% at $6.49 on the TSX.

Price: 6.51, Change: +0.10, Percent Change: +1.56